ICUI Overview

Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.

ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.

Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.

Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.

Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.

Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.

ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.

Earnings Report Overview: ICU Medical is set to report its earnings this Thursday, with analysts expecting a revenue decline of 13.3% year on year to $510.5 million, and adjusted earnings of $1.43 per share.

Previous Performance: Last quarter, ICU Medical exceeded revenue expectations by 1.7%, reporting $548.9 million, although this was an 8% decrease from the previous year.

Analyst Sentiment: Analysts have maintained their estimates for ICU Medical over the past month, indicating confidence in the company's performance, as it has only missed revenue estimates once in the last two years.

Market Context: Compared to peers like Merit Medical Systems and Intuitive Surgical, which reported strong revenue growth, ICU Medical's stock has seen a 3.5% increase over the past month, with an average analyst price target of $174.83 against its current price of $125.66.

Earnings Release Announcement: ICU Medical, Inc. will release its third quarter 2025 earnings on November 6, 2025, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.

Conference Call Access: The conference call can be accessed by phone at (800) 267-6316 with conference ID "ICUMED" and will also be available via webcast on the company's website.

Company Overview: ICU Medical is a leader in infusion systems and critical care products, serving hospital and home care settings, and is headquartered in San Clemente, California.

Contact Information: For inquiries, Brian Bonnell, CFO of ICU Medical, and John Mills, Managing Partner at ICR, can be contacted for further information.